CASI Pharmaceuticals CASIF
OTC CASIF
$0.10 +0.00 (+0.05%)
As of: Oct 21, 2026 · 10:56 AM EDT

CASI Pharmaceuticals (CASIF) Construction in Progress (2021 - 2023)

Updated

CASI Pharmaceuticals' Construction in Progress came in at $23,000 for Q4 2023, down 99.6% from $5.73 million a year earlier.

Analysis

CASI Pharmaceuticals (CASIF) Construction in Progress (2021 - 2023) Analysis & Trends

  • Going back by year, Construction in Progress was $5.73 million in FY2022 (-52.6%) and $12.1 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 CASI Pharmaceuticals 1.86 Mn -18.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 23,000.00
Dec 31, 2022 5.73 Mn
Dec 31, 2021 12.10 Mn
API Access

CASI Pharmaceuticals Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=CASIF&period=max&api_key=YOUR_API_KEY